感染

订阅

MedSci主页 / 所有栏目 / 感染

Regeneron的COVID-19抗体“鸡尾酒”REGN-COV2可大幅减少病毒载量

2020-10-29 Allan MedSci原创

COVID-19肺炎双抗体鸡尾酒疗法REGN-COV2REGN-COV2抗体REGN-COV2
关注

在标准护理中添加REGN-COV2可以减少非住院患者COVID-19的病毒载量以及缩短症状持续时间。

Regeneron Pharmaceuticals今日宣布，在COVID-19患者的II / III期研究中，其研究性抗体“鸡尾酒”REGN-COV2大幅降低了病毒载量和患者就诊次数。该公司指出，它已经与FDA共享了这些结果，FDA目前正在审查REGN-COV2治疗轻度至中度COVID-19成年患者的紧急使用授权申请。

Regeneron在9月份表示，在该试验中，在标准护理中添加REGN-COV2可以减少非住院患者COVID-19的病毒载量以及缩短症状持续时间。

Regeneron首席执行官George Yancopoulos表示：“抗COVID-19的首要工作是降低病毒载量，我们在275位患者中获得的初步数据强烈表明REGN-COV2抗体混合物可以降低病毒载量，从而有可能改善临床疗效。最新的分析涉及500多名患者，前瞻性地证实了REGN-COV2确实可以显著降低病毒载量，并进一步表明，这些病毒的减少与患者就诊次数的显著减少有关”。

 

原始出处：

https://www.firstwordpharma.com/node/1769165?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1968042, encodeId=10701968042a1, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Aug 02 04:38:53 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049342, encodeId=cbf02049342a3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 30 23:38:53 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491165, encodeId=e3d01491165e2, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574827, encodeId=535c15e482776, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2021-08-02 axin009

    #Regeneron#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1968042, encodeId=10701968042a1, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Aug 02 04:38:53 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049342, encodeId=cbf02049342a3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 30 23:38:53 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491165, encodeId=e3d01491165e2, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574827, encodeId=535c15e482776, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2021-05-30 cy0324

    #Gene#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1968042, encodeId=10701968042a1, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Aug 02 04:38:53 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049342, encodeId=cbf02049342a3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 30 23:38:53 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491165, encodeId=e3d01491165e2, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574827, encodeId=535c15e482776, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2020-10-31 grace5703

    #病毒载量#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1968042, encodeId=10701968042a1, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15269, encryptionId=9e5e15269a8, topicName=Regeneron)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon Aug 02 04:38:53 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049342, encodeId=cbf02049342a3, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 30 23:38:53 CST 2021, time=2021-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491165, encodeId=e3d01491165e2, content=<a href='/topic/show?id=fb94e0991b3' target=_blank style='color:#2F92EE;'>#病毒载量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70991, encryptionId=fb94e0991b3, topicName=病毒载量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1c1e8876950, createdName=grace5703, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574827, encodeId=535c15e482776, content=<a href='/topic/show?id=da8110295622' target=_blank style='color:#2F92EE;'>#鸡尾酒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102956, encryptionId=da8110295622, topicName=鸡尾酒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=519516025516, createdName=qblt, createdTime=Sat Oct 31 10:38:53 CST 2020, time=2020-10-31, status=1, ipAttribution=)]
    2020-10-31 qblt

    #鸡尾酒#

    0

相关资讯

礼来公司的LY-CoV555无法帮助住院COVID-19的患者

礼来公司的单克隆抗体LY-CoV555对COVID-19住院患者没有显著的临床价值。

美国国立卫生研究院（NIH）开始大型临床试验，以测试免疫调节剂治疗COVID-19的有效性

美国国立卫生研究院（NIH）已经启动了一项III期临床试验，以评估三种免疫调节剂治疗COVID-19住院患者的安全性和有效性。

新型合成干扰素Alfacyte™治疗COVID-19：已取得重大突破

合成干扰素Alfacyte™在预防SARS-CoV-2（引起COVID-19的病毒）在细胞中的传播方面，其效力要高出15-20倍。

兼具内部核衣壳（N）和外部刺突（S）蛋白的新型COVID-19疫苗候选物hAd5-COVID-19：患者已入组接种

这是一种新颖的COVID-19疫苗，它使用第二代腺病毒，可以传递SARS-CoV-2的多种蛋白质。

体外研究显示：RBT-9具有抗SARS-CoV-2活性

生物技术公司Renibus Therapeutics今天宣布，已证明其研究性疗法RBT-9具有体外抗SARS-CoV-2（引起COVID-19的病毒）活性。

JNNP:冠状病毒COVID-19对长期住院的神经病人的影响

在2月底爆发的SARS-CoV-2袭击了意大利，并迅速从伦巴第蔓延到该国其他地区，死亡人数超过31000人。尽管所有地区都报告有COVID-19患者，但确诊病例数最多的是伦巴第东部省份。1多份病例报告

拓展阅读

NEJM:抗体鸡尾酒REGN-COV2疗法可显著降低新冠肺炎患者病毒载量

REGN-COV2疗法可降低新冠肺炎病毒载量，对于基线病毒抗体阴性或载量高患者的作用更为明显，且安全性良好

总统特朗普的COVID-19该怎么治？REGN-COV2抗体“鸡尾酒疗法”

REGN-COV2是两种单克隆抗体的混合物（REGN10933和REGN10987）。